PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Demanding jobs may extend survival in some with young-onset dementia

2015-04-23
(Press-News.org) A more intellectually demanding job may be the key to living longer after developing young-onset dementia, according to health researchers. Degeneration of the frontal and temporal parts of the brain leads to a common form of dementia affecting people under the age of 65. It results in changes in personality and behavior and problems with language, but does not affect memory. "[Our] study suggests that having a higher occupational level protects the brain from some of the effects of this disease, allowing people to live longer after developing the disease," said Lauren Massimo, postdoctoral fellow, Penn State College of Nursing. Previous research has suggested that experiences such as education, occupation and mental engagement help a person develop cognitive strategies and neural connections throughout his or her life. "People with frontotemporal dementia typically live six to ten years after the symptoms emerge, but little has been known about what factors contribute to this range," said Massimo. The researchers studied the effects of education and occupation on survival rates in patients with frontotemporal dementia or with Alzheimer's disease, and report their results online today (April 22) in the journal Neurology. Massimo and colleagues reviewed the medical charts of 83 people who had an autopsy after death to confirm the diagnosis of either frontotemporal dementia or Alzheimer's disease. They also had information about patients' primary occupations. Occupations were ranked by U.S. Census categories, with jobs such as factory worker and service worker in the lowest level, trade workers and sales people in the next level, and professional and technical workers -- such as lawyers and engineers -- in the highest level. Researchers determined onset of symptoms by the earliest report from family members of persistently abnormal behavior. Survival was defined as from the time symptoms began until death. The 34 people autopsied with frontotemporal dementia had an average survival time of about seven years. The people with more challenging jobs were more likely to have longer survival times than those with less challenging jobs. People in the highest occupation level survived an average of 116 months, while people in the lower occupation group survived an average of 72 months, suggesting that individuals who had been in the professional workforce may live up to three years longer. The study found that occupational level was not associated with longer survival for the people with Alzheimer's disease dementia. The amount of education a person had did not affect the survival time in either disease. Massimo is also a postdoctoral fellow at the University of Pennsylvania Frontotemporal Degeneration Center. Ann Kolanowski, Elouise Ross Eberly Professor of nursing and director of the Hartford Center of Geriatric Nursing Excellence at Penn State; Jarcy Zee, associate research scientist, Arbor Research Collaborative for Health, Ann Arbor, Mich.; Sharon X. Xie, associate professor of biostatistics, the department of biostatistics and epidemiology, University of Pennsylvania; Corey T. McMillan, research assistant professor of neurology, Katya Rascovsky, research assistant professor of neurology, and David J. Irwin, instructor of neurology, all at the University of Pennsylvania Frontotemporal Degeneration Center; and Murray Grossman, professor of neurology, director of University of Pennsylvania Frontotemporal Degeneration Center, also collaborated on this research. The U.S. Public Health Service and the Wyncote Foundation supported this work.

INFORMATION:



ELSE PRESS RELEASES FROM THIS DATE:

Mountains warming faster, CU-Boulder, other scientists report

Mountains warming faster, CU-Boulder, other scientists report
2015-04-23
An international team of scientists is calling for urgent and temperature patterns in mountain regions after compiling evidence that high elevations could be warming faster than previously thought. Without substantially better information, people risk underestimating the severity of a number of already looming environmental challenges, including water shortages and the possible extinction of some alpine flora and fauna, according to the research team, which includes Henry Diaz and Imtiaz Rangwala from CIRES, the Cooperative Institute for Research in Environmental Sciences ...

Shetland pony midge study offers clues to curbing allergies

2015-04-23
Shetland ponies' immune response to insect bites is helping scientists understand how people could be prevented from developing allergies. The horse immune system can respond to midge bites in a way that prevents - rather than triggers - allergic reactions, researchers say. The ponies' immune response to midge bites is similar to what happens in people with allergies, the team says. Understanding what triggers allergic reactions could help researchers come up with ways to stop people developing sensitivities. It was previously thought that ponies which do not suffer ...

Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis

2015-04-23
April 23, 2015, Vienna, Austria: A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver CongressTM 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis. The research was supported by the Wellcome Trust and the NIHR. In the Liraglutide Efficacy and Action in NASH (LEAN) trial, overweight patients with biopsy-confirmed ...

Daclatasvir-sofosbuvir combination highly effective and well tolerated in patients with hepatitis C

2015-04-23
April 23, 2015, Vienna, Austria: Phase III results revealed today at The International Liver Congress™ 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients. HIV co-infection more than triples the risk of hepatitis C-related liver disease, liver failure and liver-related death. Co-infection can also complicate the management of HIV infection. In the ALLY-2 ...

Genomic analyses point to the potential of personalised care for liver cancer patients

2015-04-23
April 23, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments. Using exome sequencing - a technique for sequencing all the protein-coding genes in a genome - the study identified relationships between environmental ...

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

2015-04-23
April 23, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation. SOLAR 2 data are presented for 328 HCV genotype-1 or -4 treatment-naive or treatment-experienced ...

Pooled analysis confirms vitamin E as a treatment for non-alcoholic steatohepatitis

2015-04-23
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis. A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another ...

New survey shows that half of people with hepatitis suffer from discrimination

2015-04-23
April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver CongressTM 2015 has shown the devastating impact the infection has on their daily lives. Research conducted with the Ministry of Health in Brazil questioned 1,217 people infected with hepatitis B or C in Europe and America using an online survey tool. The aim of the research ...

Investigational anti-diabetic may offer potential for management of non-alcoholic fatty liver

2015-04-23
April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin ...

Preliminary results show Civacir prevents recurrence of hepatitis C in liver transplants

2015-04-23
April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT). The data demonstrate that intravenous Civacir given both peri- and post-LT prevents HCV-reinfection in patients who also received antiviral therapy (AVT) before their transplant operation. Civacir is a hepatitis C immune globulin (HCIG) produced from pooled plasma ...

LAST 30 PRESS RELEASES:

AI revives classic microscopy for on-farm soil health testing

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

[Press-News.org] Demanding jobs may extend survival in some with young-onset dementia